Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Appointed director

BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/16/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/22/2020 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
12/08/2020 4 Endo International plc (10% Owner) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP
Txns: Bought 7,344,955 shares @ $88.5, valued at $650M
12/02/2020 4 Chao Jennifer M (Director) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP
Txns: Disposed/sold 1,920 shares @ $0
Disposed/sold 1,726 shares @ $0
Disposed/sold 1,687 options to buy @ $37.64, valued at $63.5k
Disposed/sold 15,000 options to buy @ $41.82, valued at $627.3k
Disposed/sold 5,000 options to buy @ $55.62, valued at $278.1k
12/02/2020 4 Wegman Toby (10% Owner) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP
Txns: Disposed/sold 1,890 shares @ $0
Disposed/sold 1,726 shares @ $0
Disposed/sold 935,073 shares @ $0
12/02/2020 4 Fishman Corey N. (Director) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP
Txns: Disposed/sold 2,018 shares @ $0
Disposed/sold 6,000 options to buy @ $55.63, valued at $333.8k
12/02/2020 4 Wegman Mark N (10% Owner) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP
Txns: Gifted 2,400 shares @ $0
Disposed/sold 64,762 shares @ $0
Disposed/sold 1,726 shares @ $0
Disposed/sold 935,073 shares @ $0
12/02/2020 4 Schamroth Michael (Director) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP
Txns: Disposed/sold 115,890 shares @ $0
Disposed/sold 1,726 shares @ $0
12/02/2020 4 Truitt Joseph (CEO) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP
Txns: Disposed/sold 100,000 options to buy @ $63.72, valued at $6.4M
12/02/2020 4 Gitman Paul (Director) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP
Txns: Disposed/sold 16,890 shares @ $0
Disposed/sold 1,726 shares @ $0
12/02/2020 4 HUTCHISON PATRICK (CFO) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP
Txns: Disposed/sold 10,000 options to buy @ $56.21, valued at $562.1k
12/02/2020 4 Sherman Michael A. (Director) has filed a Form 4 on BIOSPECIFICS TECHNOLOGIES CORP
Txns: Disposed/sold 2,018 shares @ $0
Disposed/sold 6,000 options to buy @ $55.63, valued at $333.8k
12/02/2020 SC 13D/A Wegman Toby reports a 0% stake in § 240. BioSpecifics Technologies Corp.
12/02/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/02/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/02/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/02/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
12/02/2020 RW Form RW - Registration Withdrawal Request:
12/02/2020 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of BioSpecifics Technologies Corp",
"Amended and Restated By-laws of BioSpecifics Technologies Corp",
"BioSpecifics Announces Completion of Acquisition by Endo Pharmaceuticals WILMINGTON, DE - December 2, 2020 - BioSpecifics Technologies Corp. , a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX ® in North America, today announced the successful completion of its acquisition by Endo International plc for approximately $658.2 million in equity value. Endo's all-cash tender offer to acquire all of the issued and outstanding shares of BioSpecifics' common stock at a purchase price of $88.50 per share expired one minute after 11:59 p.m., New York time, on December 1, 2020. Computershare Trust Company, N.A., the depositary and paying agent for the Offer, reported that approximately 6..."
12/02/2020 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
12/02/2020 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
12/02/2020 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
11/18/2020 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
11/18/2020 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
11/18/2020 GN BioSpecifics Merger Investigation: Halper Sadeh LLP Encourages BioSpecifics Technologies Corp. Shareholders to Contact the Firm – BSTC
11/13/2020 GN SHAREHOLDER ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Investigations; Investors are Encouraged to Contact the Firm – BSTC, PE, PNM, CEIX
11/10/2020 GN Rigrodsky & Long, P.A. Reminds Investors Of Investigation of BioSpecifics Technologies Corp. Buyout
11/10/2020 GN SHAREHOLDER ALERT: Barr Law Group Investigating ZM, CBLI, BSTC, QSR; Shareholders are Encouraged to Contact the Firm
11/09/2020 10-Q Quarterly Report for the period ended September 30, 2020
11/09/2020 8-K Quarterly results
Docs: "BioSpecifics Reports Third Quarter 2020 Financial and Operating Results"
11/06/2020 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
11/06/2020 SC 14D9/A Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
11/04/2020 GN Lifshitz Law Firm, P.C. Announces Investigation of BioSpecifics Technologies Corp., Cleveland BioLabs, Inc., Concho Resources Inc., and CONSOL Energy Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy